Smith & Wesson Brands (SWBI) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
27 Dec, 2025Executive summary
Q3 net sales were $115.9 million, down 15.7% year-over-year, with gross margin at 24.1% and non-GAAP gross margin at 25.1%.
GAAP net income was $1.7 million ($0.04/share), compared to $7.9 million ($0.17/share) last year; non-GAAP net income was $962 thousand ($0.02/share).
New products accounted for over 41% of sales in Q3, with strong performance from recent launches like Bodyguard 2.0.
Market share gains in handguns were noted, despite overall market softness and a competitive environment.
Operating income for Q3 was $4.1 million (3.6% margin), down 63.4% year-over-year.
Financial highlights
Net sales for Q3 were $115.9 million, down 15.7% year-over-year; nine-month sales were $333.9 million, down 11.4%.
Gross margin was 24.1%, a 4.6% decrease from the prior year, due to lower production volumes and higher promotional costs.
Q3 operating expenses were $23.8 million, $4.3 million lower year-over-year, aided by a $2.3 million gain on property sale.
Cash used in operations was $9.8 million for Q3 and $48.1 million for nine months, compared to $25.4 million provided and $63.0 million provided in the prior year, respectively.
Interest expense rose 80.4% in Q3 due to higher debt and lower cash balances.
Outlook and guidance
Full-year revenue is expected to decline 5-10% from fiscal 2024, with Q4 likely down 2-5% year-over-year.
Margins for Q4 and full year are expected to be several percentage points lower than the prior year due to lower production and inventory reduction efforts.
Inventory levels are expected to decline during the remainder of the fiscal year.
Capital spending for the year projected at $20–$25 million.
Management believes existing capital resources and credit facilities are adequate for at least the next 12 months.
Latest events from Smith & Wesson Brands
- Q3 net sales up 17.1% to $135.7M, with higher margins and strong Q4 outlook.SWBI
Q3 20265 Mar 2026 - Double-digit growth in revenue and net income, with 2025 outlook for continued gains and higher dividends.SWBI
Q4 20243 Feb 2026 - Q1 sales fell 22.7%, but new products and margin gains support a positive full-year outlook.SWBI
Q1 202522 Jan 2026 - Board re-elections, executive pay approval, and strong financial growth highlighted the meeting.SWBI
AGM 202420 Jan 2026 - Q2 sales up 3.8% to $129.7M, but guidance cut as inflation softens demand and margins.SWBI
Q2 202511 Jan 2026 - Q2 sales dipped 3.9% but cash flow and new product momentum support a strong Q3 outlook.SWBI
Q2 20267 Dec 2025 - Director elections, say-on-pay, and a human rights proposal headline a governance-focused agenda.SWBI
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, executive pay, and auditor ratification, all board-backed.SWBI
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, executive pay, and auditor, with focus on governance and performance.SWBI
Proxy Filing1 Dec 2025